Outset Medical is trying to turn a hospital dialysis console franchise into a repeat-purchase business after a recapitalization and a reverse split. The second-quarter print showed almost no year-over-year growth even as the company signed its first fleet-refresh contract with HCA Healthcare. That contrast is the investment debate. Shareholders are being asked to treat a three-year refresh and a next-generation Tablo console as proof that a stalled installed base can become visible backlog. Consumable sales slipped in the same period, and first-half revenue still sits below the pace implied by the full-year sales range. The market is no longer pricing Outset as a growth medtech story. It is pricing the equity as a residual claim on a still-unprofitable insourcing platform whose next proof point is whether hospitals actually take the new consoles.
Console shipments recovered sequentially and service margins jumped as field operations got cheaper. Recurring cartridge and service revenue still declined slightly against last year. Management kept the full-year sales range and said most of the remaining growth arrives later in the year. Cash use slowed, and liquidity still covers the Perceptive term loan with room to spare. The counterargument is that first-half sales already ran behind the implied second-half ramp, so the guide now requires an acceleration that hospital capital budgets have not recently delivered. A mid-year amendment to the credit agreement reset both a trailing-revenue covenant and the lender warrant strike, which is not the posture of a borrower sailing through its tests.
The shares sit near the bottom of the yearly range and below book value, so the tape is not paying for a successful refresh cycle. Enterprise value after cash and the term loan is a thin residual on a platform that still loses money. What decides the case is whether HCA shipments and next-generation Tablo placements lift console volume without another consumable slump, and whether that August credit amendment was housekeeping or an early sign that the revenue test was getting tight.